Skip to main content

Table 1 Lesion characteristics in the EUS-LA and US-LA groups

From: Treatment response and preliminary efficacy of hepatic tumour laser ablation under the guidance of percutaneous and endoscopic ultrasonography

  US-LA (n = 100) EUS-LA (n = 20) p value
History of thermal ablation/Y 67 (67.0%) 16 (80.0%) 0.250
Multiple hepatic tumours/Y 64 (64.0%) 9 (45.0%) 0.112
Tumour diagnosis/HCC 77 (77.0%) 12 (60.0%) 0.113
Poorly differentiated tumour/Y 22 (22.0%) 3 (15.0%) 0.482
Recurrent lesion/Y 88 (88.0%) 20 (100%) 0.102
High-risk position/Y 56 (56.0%) 14 (70.0%) 0.246
Tumour position/left lobe 28 (28.0%) 18 (90.0%) < 0.01
Maximum tumour diameter/mean ± SD, cm 1.72 ± 0.58 1.79 ± 0.75 0.676
Multi-fibre technique/Y 69 (69.0%) 0 (0%) < 0.01
Multi-session ablation/Y 4 (4.0%) 4 (20.0%) 0.009
Delivered energy/mean ± SD, J 2927.94 ± 1690.50 2449.00 ± 1579.08 0.245
  1. US ultrasonography, EUS endoscopic ultrasonography, LA laser ablation, SD standard deviation, Hb haemoglobin, AFP alpha-fetoprotein, HCC hepatocellular carcinoma, CTA complete tumour ablation, LTP local tumour progression, Y yes